Patents by Inventor Stephen Mark Robbins
Stephen Mark Robbins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240108686Abstract: Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.Type: ApplicationFiled: June 5, 2023Publication date: April 4, 2024Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Jennifer Joy Rahn, Arthur Wing SZE Lau, Daniel Abraham Muruve, Saurav Roy Choudhury, Liane Babes, Paul Kubes
-
Patent number: 11666631Abstract: Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.Type: GrantFiled: July 8, 2019Date of Patent: June 6, 2023Assignee: Arch Biopartners, Inc.Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Jennifer Joy Rahn, Arthur Wing Sze Lau, Daniel Abraham Muruve, Saurav Roy Choudhury, Liane Babes, Paul Kubes
-
Publication number: 20220251140Abstract: Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.Type: ApplicationFiled: February 14, 2022Publication date: August 11, 2022Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Daniel Abraham Muruve, Saurav Roy Choudhury, Jennifer Joy Rahn, Arthur Wing Sze Lau, Justin MacDonald, Liane Babes, Paul Kubes
-
Patent number: 11286278Abstract: Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.Type: GrantFiled: December 2, 2019Date of Patent: March 29, 2022Assignee: Arch BioPartners, Inc.Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Daniel Abraham Muruve, Saurav Roy Choudhury, Jennifer Joy Rahn, Arthur Wing Sze Lau, Justin MacDonald, Liane Babes, Paul Kubes
-
Patent number: 11083773Abstract: Disclosed are novel peptides comprising SEQ ID NO: 1 and modifications thereof, which are effective in blocking leukocyte recruitment. The disclosed peptides are useful for treating diseases associated with leukocyte recruitment for example inhibiting metastasis of a solid tumor to the liver and lungs and for treating sepsis. Also disclosed are methods of screening for compounds having the ability to block leukocyte recruitment.Type: GrantFiled: September 13, 2018Date of Patent: August 10, 2021Assignee: ARCH CANCER THERAPEUTICS, INC.Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Jennifer Joy Rahn, Paul Kubes
-
Publication number: 20200223888Abstract: Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.Type: ApplicationFiled: December 2, 2019Publication date: July 16, 2020Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Daniel Abraham Muruve, Saurav Roy Choudhury, Jennifer Joy Rahn, Arthur Wing Sze Lau, Justin MacDonald, Liane Babes, Paul Kubes
-
Publication number: 20200078442Abstract: Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.Type: ApplicationFiled: July 8, 2019Publication date: March 12, 2020Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Jennifer Joy Rahn, Arthur Wing SZE Lau, Daniel Abraham Muruve, Saurav Roy Choudhury, Liane Babes, Paul Kubes
-
Publication number: 20200038473Abstract: Disclosed are novel peptides comprising SEQ ID NO: 1 and modifications thereof, which are effective in blocking leukocyte recruitment. The disclosed peptides are useful for treating diseases associated with leukocyte recruitment for example inhibiting metastasis of a solid tumor to the liver and lungs and for treating sepsis. Also disclosed are methods of screening for compounds having the ability to block leukocyte recruitment.Type: ApplicationFiled: September 13, 2018Publication date: February 6, 2020Applicant: ARCH CANCER THERAPEUTICS, INC.Inventors: STEPHEN MARK ROBBINS, DONNA LORRAINE SENGER, JENNIFER JOY RAHN, PAUL KUBES
-
Patent number: 10493127Abstract: Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.Type: GrantFiled: August 11, 2016Date of Patent: December 3, 2019Assignee: Arch Biopartners, Inc.Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Jennifer Joy Rahn, Arthur Wing Sze Lau, Daniel Abraham Muruve, Saurav Roy Choudhury, Liane Babes, Paul Kubes
-
Publication number: 20170258872Abstract: Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.Type: ApplicationFiled: August 11, 2016Publication date: September 14, 2017Inventors: STEPHEN MARK ROBBINS, DONNA LORRAINE SENGER, JENNIFER JOY RAHN, ARTHUR WING SZE LAU, DANIEL ABRAHAM MURUVE, SAURAV ROY CHOUDHURY
-
Publication number: 20170072006Abstract: Disclosed are novel peptides comprising SEQ ID NO: 1 and modifications thereof, which are effective in blocking leukocyte recruitment. The disclosed peptides are useful for treating diseases associated with leukocyte recruitment for example inhibiting metastasis of a solid tumor to the liver and lungs and for treating sepsis. Also disclosed are methods of screening for compounds having the ability to block leukocyte recruitment.Type: ApplicationFiled: August 31, 2016Publication date: March 16, 2017Applicant: ARCH CANCER THERAPEUTICS, INC.Inventors: STEPHEN MARK ROBBINS, DONNA LORRAINE SENGER, JENNIFER JOY RAHN, PAUL KUBES
-
Patent number: 9464114Abstract: Disclosed are novel peptides comprising SEQ ID NO: 1 and modifications thereof, which are effective in blocking leukocyte recruitment. The disclosed peptides are useful for treating diseases associated with leukocyte recruitment for example inhibiting metastasis of a solid tumor to the liver and lungs and for treating sepsis. Also disclosed are methods of screening for compounds having the ability to block leukocyte recruitment.Type: GrantFiled: February 13, 2015Date of Patent: October 11, 2016Assignee: ARCH CANCER THERAPEUTICS, INC.Inventors: Stephen Mark Robbins, Donna Lorraine Senger, Jennifer Joy Rahn, Paul Kubes
-
Publication number: 20150374853Abstract: A method of diagnosing and treating a human glioblastoma multiforme (GBM) brain tumor in a subject is disclosed. The method includes administering to the subject, an effective amount of composition having a peptide 12-20 amino acid residues in length and selected for its ability to bind preferentially to a subtype of human GBM cells identified as brain tumor initiating cells (BTICs) or highly invasive glioma cells (HIGCs).Type: ApplicationFiled: July 1, 2015Publication date: December 31, 2015Inventors: STEPHEN MARK ROBBINS, JENNIFER RAHN, DONNA LORRAINE SENGER
-
Publication number: 20150225459Abstract: Disclosed are novel peptides comprising SEQ ID NO: 1 and modifications thereof, which are effective in blocking leukocyte recruitment. The disclosed peptides are useful for treating diseases associated with leukocyte recruitment for example inhibiting metastasis of a solid tumor to the liver and lungs and for treating sepsis. Also disclosed are methods of screening for compounds having the ability to block leukocyte recruitment.Type: ApplicationFiled: February 13, 2015Publication date: August 13, 2015Applicant: ARCH CANCER THERAPEUTICS, INC.Inventors: STEPHEN MARK ROBBINS, DONNA LORRAINE SENGER, JENNIFER JOY RAHN, PAUL KUBES
-
Patent number: 9095541Abstract: A method of diagnosing and treating a human glioblastoma multiforme (GBM) brain tumor in a subject is disclosed. The method includes administering to the subject, an effective amount of composition having a peptide 12-20 amino acid residues in length and selected for its ability to bind preferentially to a subtype of human GBM cells identified as brain tumor initiating cells (BTICs) or highly invasive glioma cells (HIGCs).Type: GrantFiled: June 2, 2011Date of Patent: August 4, 2015Assignee: Arch Cancer Therapeutics, Inc.Inventors: Stephen Mark Robbins, Jennifer Rahn, Donna Lorraine Senger
-
Patent number: 8530429Abstract: A method of diagnosing and treating a human glioblastoma multiforme (GBM) brain tumor in a subject is disclosed. The method includes administering to the subject, an effective amount of composition having a peptide 12-20 amino acid residues in length and selected for its ability to bind preferentially to a subtype of human GBM cells identified as brain tumor initiating cells (BTICs) or highly invasive glioma cells (HIGCs). Also disclosed are a phage-display screening method for identifying such therapeutic peptides, and peptides that hind specifically to BTICs or HIGCs.Type: GrantFiled: November 19, 2010Date of Patent: September 10, 2013Assignee: Arch Cancer Therapeutics, Inc.Inventors: Stephen Mark Robbins, Jennifer Rahn, Donna Lorraine Senger
-
Publication number: 20110274619Abstract: A method of diagnosing and treating a human glioblastoma multiforme (GBM) brain tumor in a subject is disclosed. The method includes administering to the subject, an effective amount of composition having a peptide 12-20 amino acid residues in length and selected for its ability to bind preferentially to a subtype of human GBM cells identified as brain tumor initiating cells (BTICs) or highly invasive glioma cells (HIGCs).Type: ApplicationFiled: June 2, 2011Publication date: November 10, 2011Applicant: ARCH CANCER THERAPEUTICS, INC.Inventors: Stephen Mark Robbins, Jennifer Rahn, Donna Lorraine Senger
-
Publication number: 20110129418Abstract: A method of diagnosing and treating a human glioblastoma multiforme (GBM) brain tumor in a subject is disclosed. The method includes administering to the subject, an effective amount of composition having a peptide 12-20 amino acid residues in length and selected for its ability to bind preferentially to a subtype of human GBM cells identified as brain tumor initiating cells (BTICs) or highly invasive glioma cells (HIGCs). Also disclosed are a phage-display screening method for identifying such therapeutic peptides, and peptides that hind specifically to BTICs or HIGCs.Type: ApplicationFiled: November 19, 2010Publication date: June 2, 2011Applicant: ARCH CANCER THERAPEUTICS, INC.Inventors: Stephen Mark Robbins, Jennifer Rahn, Donna Lorraine Senger